MDCX vs. MRK
MDCX (Medicus Pharma Ltd) and MRK (Merck & Co., Inc.) are both stocks. Both are in the Healthcare sector — MDCX in Biotechnology, MRK in Drug Manufacturers - General. Over the past year, MDCX returned -89.29% vs 69.70% for MRK. Their 0.09 correlation means their historical movements had little consistent relationship.
Performance
MDCX vs. MRK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDCX achieves a -82.01% return, which is significantly lower than MRK's 25.51% return.
MDCX
- 1D
- 4.80%
- 1M
- -33.89%
- 6M
- -76.87%
- YTD
- -82.01%
- 1Y
- -89.29%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -75.77%
MRK
- 1D
- 0.32%
- 1M
- 0.49%
- 6M
- 19.80%
- YTD
- 25.51%
- 1Y
- 69.70%
- 3Y*
- 10.70%
- 5Y*
- 14.64%
- 10Y*
- 12.26%
- ALL TIME*
- 12.54%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $505.47K | $499.43K | $773.71K | |
| $997.19M | $1.08B | $1.21B |
MDCX vs. MRK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
MDCX Medicus Pharma Ltd | -82.01% | -37.04% | -21.61% |
MRK Merck & Co., Inc. | 25.51% | 9.79% | 1.80% |
Correlation
The correlation between MDCX and MRK is 0.10, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.10 |
Correlation (All Time) Calculated using the full available price history since Nov 14, 2024 | 0.09 |
Fundamentals
MDCX:
$6.07M
MRK:
$321.62B
MDCX:
-$1.92
MRK:
$3.59
MDCX:
$0.00
MRK:
$65.59B
MDCX:
$0.00
MRK:
$49.79B
MDCX:
-$36.18M
MRK:
$22.69B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDCX vs. MRK — Risk / Return Rank
MDCX
MRK
MDCX vs. MRK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDCX | MRK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.34 | ||
| Sortino ratioReturn per unit of downside risk | -5.08 | ||
| Omega ratioGain probability vs. loss probability | 0.83 | 1.44 | -0.61 |
| Calmar ratioReturn relative to maximum drawdown | -0.98 | 6.39 | -7.37 |
| Martin ratioReturn relative to average drawdown | -1.45 | 16.11 | -17.56 |
Loading charts...
Drawdowns
MDCX vs. MRK - Drawdown Comparison
The maximum MDCX drawdown since its inception was -96.62%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for MDCX and MRK.
Loading charts...
Drawdown Indicators
| MDCX | MRK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.62% | -68.61% | -28.01% |
Max Drawdown (1Y)Largest decline over 1 year | -90.62% | -11.37% | -79.25% |
Max Drawdown (3Y)Largest decline over 3 years | — | -43.44% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -43.44% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -43.44% | — |
Current DrawdownCurrent decline from peak | -96.46% | -1.23% | -95.23% |
Average DrawdownAverage peak-to-trough decline | -60.11% | -18.79% | -41.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 61.30% | 4.50% | +56.80% |
Volatility
MDCX vs. MRK - Volatility Comparison
Medicus Pharma Ltd (MDCX) has a higher volatility of 33.61% compared to Merck & Co., Inc. (MRK) at 8.23%. This indicates that MDCX's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDCX | MRK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 33.61% | 8.23% | +25.38% |
Volatility (6M)Calculated over the trailing 6-month period | 123.42% | 19.68% | +103.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 126.72% | 27.87% | +98.85% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 130.72% | 24.10% | +106.62% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 130.72% | 23.13% | +107.59% |
Dividends
MDCX vs. MRK - Dividend Comparison
MDCX has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 2.58%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDCX Medicus Pharma Ltd | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MRK Merck & Co., Inc. | 2.58% | 3.12% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% |
Financials
MDCX vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Medicus Pharma Ltd and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MDCX and MRK have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MDCX has higher volatility (33.61%) compared to MRK (8.23%). In terms of maximum drawdown, MDCX dropped -96.62% vs MRK's -68.61%.
MRK currently has the higher Sharpe Ratio (2.64 vs -0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDCX and MRK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer